← Back to Search

Diagnostic Imaging

Metabolic MRI for Brain Tumor

Phase < 1
Recruiting
Led By Benjamin M Ellingson
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
AIM 2: Newly diagnosed or recurrent suspected or confirmed glioma (low or high grade), 10 IDH mutant and 10 IDH wild type gliomas, clinically indicated for resective surgery or biopsy, age 18+, tumor size > 1x1x1 cm (measurable)
AIM 1: Healthy volunteers with no evidence of brain tumors or neurologic disease, age 18+
Must not have
AIM 3: Cannot safely perform an MRI or use of MRI contrast agents, age < 18
AIM 2: Cannot safely perform an MRI or use of MRI contrast agents, age < 18
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new MRI sequence to better detect and diagnose brain tumors.

Who is the study for?
This trial is for adults over 18 with newly diagnosed or recurrent glioma, a type of brain tumor. Healthy volunteers are also needed for part of the study. Participants must be able to safely undergo MRI scans and have tumors measurable at least 1cm in size. Those receiving immunotherapy for recurrent glioma can join too.
What is being tested?
The trial is testing a new multinuclear metabolic MRI sequence designed to improve early detection, diagnosis, prognosis, and treatment planning in brain cancer patients. It involves biospecimen collection and diagnostic imaging using this novel technology.
What are the potential side effects?
Since the interventions involve non-invasive imaging techniques like MRI rather than drugs or surgery, side effects are minimal but may include discomfort from lying still during the scan or reactions to contrast agents if used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 or older with a suspected or confirmed glioma, indicated for surgery, and my tumor is larger than 1cm³.
Select...
I am over 18 and do not have any brain tumors or neurological diseases.
Select...
I am 18 or older with recurrent glioma and am in an immunotherapy trial or need immunotherapy.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am under 18 or cannot safely have an MRI with contrast.
Select...
I am under 18 or cannot safely have an MRI with contrast.
Select...
I am under 18 and cannot safely have an MRI.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
NHE1 expression
Total sodium concentration
Tumor metabolism

Trial Design

1Treatment groups
Experimental Treatment
Group I: Basic science (MRI, metabolic imaging, tissue collection)Experimental Treatment3 Interventions
AIM 1: Previous scan data from healthy subjects is collected and analyzed. AIM 2: Patients undergo MRI. Patients also undergo collection of tissue samples for IHC analysis. AIM 3: Patients undergo multinuclear metabolic imaging before and after immunotherapy and prior to surgical resection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~2020
Magnetic Resonance Imaging
2017
Completed Phase 3
~1160

Find a Location

Who is running the clinical trial?

United States Department of DefenseFED
891 Previous Clinical Trials
332,418 Total Patients Enrolled
Jonsson Comprehensive Cancer CenterLead Sponsor
369 Previous Clinical Trials
29,369 Total Patients Enrolled
Benjamin M EllingsonPrincipal InvestigatorUCLA / Jonsson Comprehensive Cancer Center
2 Previous Clinical Trials
58 Total Patients Enrolled

Media Library

Simultaneous Multinuclear Metabolic MRI (Diagnostic Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT05045027 — Phase < 1
Brain Tumor Research Study Groups: Basic science (MRI, metabolic imaging, tissue collection)
Brain Tumor Clinical Trial 2023: Simultaneous Multinuclear Metabolic MRI Highlights & Side Effects. Trial Name: NCT05045027 — Phase < 1
Simultaneous Multinuclear Metabolic MRI (Diagnostic Imaging) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05045027 — Phase < 1
~23 spots leftby Sep 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top